SCN11A

Sodium channel protein type 11 subunit alpha · Q9UI33 · SCN11A on Sugi Atlas →

3,327 patent compounds predicted against SCN11A, 2,621 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Mibefradil (SCHEMBL6386022)	0.67	2/20
Diltiazem (SCHEMBL6789503)	0.62	2/20
Noxiptiline (SCHEMBL49824)	0.49	2/20
SCHEMBL5225360	0.48	2/20
SCHEMBL7294678	0.48	2/20
SCHEMBL7287790	0.44	2/20
SCHEMBL5225757	0.43	2/20
SCHEMBL6270050	0.40	2/20
SCHEMBL4178165	0.38	2/20
Mexiletine (SCHEMBL16081)	1.00	1/20
(R)-Mexiletine (SCHEMBL16082)	1.00	1/20
Diltiazem (SCHEMBL17776)	1.00	1/20
Ajmaline (SCHEMBL18950)	1.00	1/20
Ajmaline (SCHEMBL34501)	1.00	1/20
Mibefradil (SCHEMBL39551)	1.00	1/20
Sertindole (SCHEMBL112092)	1.00	1/20
Cifenline (SCHEMBL122806)	1.00	1/20
Tedisamil (SCHEMBL157918)	1.00	1/20
Diltiazem (SCHEMBL614334)	1.00	1/20
Diltiazem (SCHEMBL676914)	1.00	1/20

Clinical trials — most relevant to SCN11A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations	PHASE4	COMPLETED
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy	PHASE3	COMPLETED
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome	PHASE3	RECRUITING
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome	PHASE1/PHASE2	COMPLETED
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)	PHASE1/PHASE2	RECRUITING
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome	PHASE1/PHASE2	RECRUITING
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome	PHASE2	COMPLETED
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study	nan	UNKNOWN
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom	nan	RECRUITING
A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy	nan	COMPLETED
Treatment of Gait Disorders in Children With Dravet Syndrome	nan	COMPLETED
Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation	nan	RECRUITING
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)	nan	COMPLETED
fMRI-study in Patients With Small Fiber Neuropathy	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
Impact on Risk Stratification of Overlap Syndrome Phenotype in Patients With E1784K Mutation in SCN5A	nan	COMPLETED
Classical Trigeminal Neuralgia and Sodium Channel Mutations	nan	COMPLETED
Role of SNP and DIGOXIN Response in Atrial Fibrillation Patients	nan	COMPLETED
EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype Heterogeneity	nan	UNKNOWN
Transcranial Magnetic Stimulation to Measure Cortical Excitability in Dravet Syndrome	nan	UNKNOWN
GABA Biomarkers in Dravet Syndrome	nan	RECRUITING
Factors Affecting Salt Intake in Young Adults	nan	UNKNOWN
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases	nan	UNKNOWN
Heart and Skeletal Muscle Problems in Neuroacanthocytosis	nan	COMPLETED
ST-segment Elevation as an AF Endophenotype	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SCN11A binder may also engage these)

Protein	Name	Similarity
Q9R053	—	0.996	Q9R053 →
Q62968	—	0.995	Q62968 →
SCN7A	Sodium channel protein type 7 subunit alpha	0.994	landscape →
P15390	—	0.994	P15390 →
O88457	—	0.994	O88457 →
SCN10A	Sodium channel protein type 10 subunit alpha	0.993	landscape →
Q6QIY3	—	0.993	Q6QIY3 →
F1LQQ7	—	0.993	F1LQQ7 →
B1AYL1	—	0.993	B1AYL1 →
Q28371	—	0.993	Q28371 →
P15389	—	0.992	P15389 →
Q28644	—	0.992	Q28644 →
SCN5A	Sodium channel protein type 5 subunit alpha	0.992	landscape →
P02719	—	0.991	P02719 →
SCN2A	Sodium channel protein type 2 subunit alpha	0.991	landscape →
O08562	—	0.991	O08562 →
Q6AXP6	—	0.991	Q6AXP6 →
SCN3A	Sodium channel protein type 3 subunit alpha	0.991	landscape →
Q62205	—	0.990	Q62205 →
Q9JJV9	—	0.990	Q9JJV9 →
O46669	—	0.990	O46669 →
A2APX8	—	0.990	A2APX8 →
Q9ER60	—	0.989	Q9ER60 →
O97531	—	0.989	O97531 →
P04775	—	0.989	P04775 →
CACNA1G	Voltage-dependent T-type calcium channel subunit alpha-1G	0.988	landscape →
O88420	—	0.988	O88420 →
P08104	—	0.988	P08104 →
Q96P56	—	0.988	Q96P56 →
SCN8A	Sodium channel protein type 8 subunit alpha	0.987	landscape →